Plasma is the liquid component of the blood that is of a clear yellowish or light brown color. Plasma-derived medicinal products (PDMPs) are prepared industrially from human plasma and include products such as coagulation factors, albumin, and immunoglobulins which are life-saving therapeutics for several chronic and acute life-threatening diseases such as hereditary coagulation disorders, hereditary immunodeficiency diseases, and others.
The global plasma derived medicine market is estimated to be valued at US$ 33,450 million in 2021 and expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028).
Figure 1. Global Plasma Derived Medicine Market Share (%) in Terms of Value, by Product Type, 2021
Increasing product launches are expected to drive the market growth during the forecast period.
Increasing product launches are expected to boost the growth of the global plasma derived medicine market over the forecast period. For instance, in November 2021, Grifols, S.A., a leading global producer of plasma-derived medicines, announced the launch of albumin ALBUTEIN FlexBag (Albumin [Human] U.S.P.) in 5% and 25% concentrations. ALBUTEIN is derived from plasma and is indicated for cardiopulmonary bypass procedures, hypovolemia, hypoalbuminemia, and plasma exchange.
|Base Year:||2020||Market Size in 2021:||US$ 33,450 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||6.8%||2028 Value Projection:||US$ 53,136.4 Mn|
Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG
|Restraints & Challenges:||
Figure 2. Global Plasma Derived Medicine Market Share (%), by Distribution Channel, 2021
The increasing establishment of new plasma collection centers is expected to drive the market growth during the forecast period.
The increased establishment of new plasma collection centers by the key market players is expected to drive the market growth during the forecast period. For instance, in January 2022, ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced that it had received U.S. Food and Drug Administration (FDA) approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina.
Global Plasma Derived Medicine Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.
There is limited knowledge available about plasma-derived therapeutics; however, the COVID-19 pandemic brought attention to this type of treatment and highlighted its potential applications. The key players started carrying out various research activities aimed at determining the use of plasma-derived medicines to treat the COVID-19 infection. For instance, the CoVIg-19 Plasma Alliance was formed in response to the pandemic in April 2020 by major global players in plasma-derived pharmaceutical products market, including LFB, a pharmaceutical company specializing in biological medicinal products, to speed up the development of a hyperimmune immunoglobulin experimental therapy for the treatment of the COVID-19.
However, as a result of the worldwide lockdown, lower volumes of plasma donations began to appear. According to an article published by the National Center for Biotechnology Information (NCBI) in April 2020, the COVID-19 outbreak resulted in a considerable drop in blood donations when compared to the previous year, owing to the COVID-19-related cautions made by the government to avoid crowds, such as lockdowns. Furthermore, the number of asymptomatic cases increased, making it more difficult to diagnose, and consequently, posing an indirect risk to blood collection safety. Increased cases of COVID-19 had also caused widespread fear among blood donors, causing a negative impact on the blood community. Therefore, these factors impacted negatively on the global plasma derived medicine market. However, increasing research activities carried out by researchers are expected to drive the market growth over the forecast period.
Global Plasma Derived Medicine Market: Restraint
The major factors that hinder the growth of the global plasma derived medicine market include the high cost of plasma-derived medicines and high time required in preparing plasma-derived medicines.
Major players operating in the global plasma derived medicine market include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG
Plasma-derived medicinal products are pharmaceuticals or medicines produced from human plasma which is the liquid portion of the blood and consists of approximately 90% water. It contains over 120 different proteins that take on functions vital to life, such as fighting infections or clotting of blood to stop bleeding after an injury. Albumin, immunoglobulin, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma. PDMPs (plasma-derived medicinal products) are used in medical treatment and prophylaxis. Plasma products play an important role in managing autoimmune disorders, bleeding emergencies, and a number of chronic conditions such as hemophilia, congenital and acquired immunodeficiencies, and other inherited protein disorders.
Increasing product approvals by regulatory bodies for plasma-derived medicines are expected to drive the global plasma derived medicine market over the forecast period. For instance, in July 2021, Octapharma AG, a company that develops and produces high-quality human proteins from human plasma and human cell lines, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its Octagam 10%, an immune globulin intravenous (human) liquid preparation derived from large pools of human plasma, the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
Moreover, increasing marketing approvals by the regulatory bodies for plasma-derived medicines is expected to drive the global plasma derived medicine market over the forecast period. For instance, in January 2022, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, announced that the National Medical Products Administration (NMPA) for China granted BPL a license to market ALBUMINEX 25% product in China.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.